Fig. 5.

Neutralisation of IL-1β blocks low concentration IL-1β-mediated IAPP release. Following 48 h treatment, release of IAPP (a) and insulin (b) from hIAPP-expressing islets were significantly increased by 4 pg/ml IL-1β (black squares) compared with vehicle (black circles). The release of IAPP (a) and insulin (b) mediated by low concentration IL-1β (black squares) was reduced when islets were co-treated with 0.4 μg/ml of IL-1β neutralising antibody (white squares). Data are presented as mean ± SEM. n=4. *p<0.05, **p<0.01. CTL, control (vehicle); NAb, IL-1β neutralising antibody